Abstract
Objective We hypothesise that subclinical myocardial injury during midlife, indexed by increases in cardiac troponin I, is associated with accelerated cognitive decline, smaller structural brain volume, and higher risk of dementia.
Design Longitudinal cohort study
Setting Civil service departments in London (Whitehall II study)
Participants 5985 participants aged 45-69 had cardiac troponin I measured by high-sensitivity assay at baseline (1997-99) for prospective cohort analyses. A nested case-control sample of 3475 participants (695 dementia cases and 2780 matched controls) was used for backward cardiac troponin I trajectory analysis. 641 participants provided magnetic resonance imaging (MRI) scans for brain volume analysis.
Main outcome measures Incident dementia cases were ascertained from national hospital episode statistics, mental health and mortality registers until 2023. Cognitive testing was performed at six waves over 25 years (1997-99, 2002-04, 2007-09, 2012-13, 2015-16, 2019-22). Brain volume metrics were derived from structural MRI scans (2012-16).
Results For prospective cohort analyses, 606 (10.1%) incident cases of dementia were recorded over a median follow-up of 24.8 years. Doubling of cardiac troponin was associated with 11% higher risk of dementia (HR=1.11, 95% CI: 1.04 to 1.19). Participants with increased cardiac troponin at baseline had a faster decline of cognitive function with age. Compared to participants with concentrations below the limit of quantitation (<2.5 ng/L), those in the upper third (>5.2 ng/L) had similar global cognitive z score at age 60, but had 0.10 (95% CI: 0.02 to 0.18) standard deviations lower score at age 80, and 0.19 (0.03 to 0.35) standard deviations lower score at age 90. Participants with dementia had increased cardiac troponin concentrations compared with those without dementia between 7 and 25 years before diagnosis. Compared to those with low cardiac troponin level (<2.5 ng/L at baseline) those with concentrations >5.2 ng/L had lower grey matter volume and higher hippocampal atrophy 15 years later, equivalent to ageing effects of 2.7 and 3 years, respectively.
Conclusions Subclinical myocardial injury at midlife was associated with higher dementia risk in later life.
What is already known on this topic A systematic review of observational studies suggests higher cardiac troponin concentrations are associated with poorer cognitive function and increased dementia risk. Formal meta-analysis was not performed due to the small number of available studies.
Existing studies assessed cardiac troponin once and had relatively short follow-up time. Evidence is lacking on the time course of cardiac troponin level before diagnosis in dementia cases compared with controls.
What this study adds People with increased cardiac troponin I concentrations in mid-life had faster cognitive decline and were more likely to develop dementia over 25 years of follow-up. Backward trajectory analysis using three measurements using a high-sensitivity assay showed that people with dementia had higher cardiac troponin levels as early as 25 years before dementia diagnosis compared with those without dementia. People in the magnetic resonance imaging subcohort with higher cardiac troponin I concentrations at baseline had lower grey matter volume and hippocampal atrophy 15 years later.
Subclinical myocardial injury in midlife, by indicating long-term risk of dementia, is unlikely to be due to preclinical changes before dementia onset and may lie on the causal pathway to dementia.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support for the Whitehall II study from the Wellcome Trust, the National Institute on Aging, NIH, the British Heart Foundation and UK Medical Research Council; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. KPE reports receiving consulting fees for being in the expert panel for European Research Council, Flemish Science Foundation, and European Science Foundation. JD reports consulting fees and honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk, and Bayer. NLM reports honoraria from Abbott Diagnostics, Siemens Healthineers, and Roche Diagnostics.
Funding Statement
The Whitehall II study has been supported by grants from the Wellcome Trust, UK (221854/Z/20/Z), the UK Medical Research Council (Y014154, K013351, R024227, S011676); the British Heart Foundation (PG/11/63/29011, RG/13/2/30098, RG/16/11/32334); the British Health and Safety Executive; the British Department of Health; the National Heart, Lung, and Blood Institute (R01HL036310); the National Institute on Aging, National Institute of Health (R01AG013196, R01AG034454); the Economic and Social Research Council (ES/J023299). The Whitehall II imaging substudy (KPE) was supported by the Medical Research Council (G1001354), the HDH Wills 1965 Charitable Trust (English Charity No 1117747), and the Gordon Edward Small?s Charitable Trust (Scottish Charity No SC008962). DMK is supported by the British Heart Foundation through an Intermediate Basic Science Research Fellowship. NLM is supported by the British Heart Foundation through a Chair Award (CH/F/21/90010), Programme Grant (RG/20/10/34966), and a Research Excellence Award (RE/24/130012). The study was supported by an investigator-initiated study grant from the Siemens Healthineers to the University of Edinburgh. YC is supported by the Wellcome Early-Career Award (227639/Z/23/Z). EJB was supported by the Economic and Social Research Council (ES/T014377).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent from participants and research ethics approvals were renewed at each contact. Ethical approval was from the University College London Hospital Committee on the Ethics of Human Research (reference number 85/0938).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Whitehall II data cannot be shared publicly because of constraints dictated by the study's ethics approval and IRB restrictions. The Whitehall II data are available for sharing within the scientific community. Researchers can apply for data access at https://www.ucl.ac.uk/psychiatry/research/mental-health-older-people/whitehall-ii/data-sharing.
